FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3128448500> ?p ?o ?g. }

• W3128448500 endingPage "230" @default.
• W3128448500 startingPage "186" @default.
• W3128448500 abstract "Two recent studies published in this journal focused on SARS-CoV-2 infection among hospital workers (HWs), the first one reported the prevalence of SARS-CoV-2 carriage among HWs and the second, the clinical presentation of symptomatic HWs in order to identify new cases as early as possible and to stop nosocomial transmission1Brown C.S. Clare K. Chand M. Andrews J. Auckland C. Beshir S. et al.Snapshot PCR surveillance for SARS-CoV-2 in hospital staff in England.J Infect. Sep 2020; 81 (PubMed PMID:32615198): 427-434Abstract Full Text Full Text PDF PubMed Scopus (20) Google Scholar,2Jary A. Flandre P. Chabouis A. Nguyen S. Marot S. Burrel S. et al.Clinical presentation of Covid-19 in health care workers from a French University Hospital.J Infect. 2020 Sep; 81 (PubMed PMID:32579992): e61-e63Abstract Full Text Full Text PDF PubMed Scopus (6) Google Scholar. The objective of the present study was to estimate within the hospital, the risk of in-hospital HWs infection following a high-risk exposure to SARS-CoV-2-infected subject without personal protective equipment. We conducted the CoV-CONTACT study, a prospective cohort which included HWs, hereafter referred to as “contacts” with an high risk exposure to an SARS-CoV-2-infected person (either a patient or a colleague) hereafter referred to as “index”, in the 1000 bed Bichat Claude Bernard University Hospital (Paris, France) between March, 3rd 2020 and April, 27th 20203Lescure F.X. Bouadma L. Nguyen D. Parisey M. Wicky P.H. Behillil S. et al.Clinical and virological data of the first cases of COVID-19 in Europe: a case series.Lancet Infect Dis. Jun 2020; 20 (PubMed PMID:32224310): 697-706Abstract Full Text Full Text PDF PubMed Scopus (773) Google Scholar. Exposure was considered to be at high-risk of SARS-CoV-2 transmission if it occurred i) face-to-face, within one meter and without protective surgical or FFP2/N95 mask, and ii) during a discussion or while the index had an episode of coughing or sneezing, and iii) in the 72 h prior to, or following the virological diagnosis, or during the symptomatic period of the index. Following exposure and upon written informed consent, daily symptoms were self-reported for 30 days; nasopharyngeal swabs for SARS-CoV-2 RT-PCR were performed at inclusion and at days 3, 5, 7 and 12; SARS-CoV-2 IgG serology (LuLISA N and EuroIMMUN4Anna F. Goyard S. Lalanne A. Nevo F. Gransagne M. Souque P. et al.High seroprevalence but short-lived immune response to SARS-CoV-2 infection in Paris.medRxiv. 2020; https://doi.org/10.1101/2020102520219030Crossref Google Scholar,5Theel E.S. Harring J. Hilgart H. Granger D. Performance characteristics of four high-throughput immunoassays for detection of IgG antibodies against SARS-CoV-2.J Clin Microbiol. Jun 8 2020; (PubMed PMID:32513859)Crossref Scopus (142) Google Scholar) was assessed at inclusion and at day 30. Confirmed infection was defined by positive RT-PCR or seroconversion, and possible infection by one general and one specific symptom for two consecutive days. SARS-CoV-2 seroconversion was defined as the apparition of a positive SARS-CoV-2 serology at the D30 visit, or as an at least two-fold increase of the LuLISA signal or EuroIMMUN ratio between inclusion and day 30. The primary endpoint was confirmed or possible SARS-CoV-2 infection, hereafter referred to as “SARS-CoV-2 infection”. The 146 analysed contacts were exposed to 42 COVID-19 index. No contacts worked in a front-line COVID-19 unit (Table 1). Exposure to patient decreased from 67.4% (56/83) before March, 18th (the date of the widespread use of masks in the hospital) to 15.9% (10/63) after March, 18th.Table 1Characteristics of the 146 contacts with high-risk exposure to SARS-CoV-2 included in the CoV-CONTACT cohort, according to the infection status at D30.VariableAll contacts (N = 146)Contacts with SARS-CoV-2 infection (N = 63)Contacts with no SARS-CoV-2 infection (N = 83)OR [95%CI]p-valueaOR [95%CI]p-valueContact characteristicsAge (year)35 [29;46] (N = 146)35 [28.5;45.5] (N = 63)35 [30;47] (N = 83)0.99 [0.96;1.02]0.46Male gender35/146 (24%)11/63 (17.5%)24/83 (28.9%)0.52 [0.23;1.14]0.11HW functionsMedical doctor / Resident / Midwife49/146 (33.6%)14/63 (22.2%)35/83 (42.2%)1 (ref)–1 (ref)–Registered nurse / Certified nurse assistant /Physiotherapists / Hospital Students74/146 (50.7%)36/63 (57.1%)38/83 (45.8%)2.37 [1.11;5.22]0.0281.76[0.78;4.03]0.18Non-caregiver HWs23/146 (15.8%)13/63 (20.6%)10/83 (12%)3.25 [1.17;9.36]0.0254.06 [1.42;12.18]0.010Coexisting conditionsObesity (BMI > 30 Kg/m²)27/146 (18.5%)13/63 (20.6%)14/83 (16.9%)1.28 [0.55;2.98]0.56Tobacco use36/146 (24.7%)17/63 (27%)19/83 (22.9%)1.24 [0.58;2.66]0.57Cardiopathy8/146 (5.5%)5/63 (7.9%)3/83 (3.6%)2.3 [0.54;11.57]0.27Chronic respiratory disease21/146 (14.4%)7/63 (11.1%)14/83 (16.9%)0.62 [0.22;1.59]0.33Chronic kidney disease2/146 (1.4%)2/63 (3.2%)0/83 (0%)NE0.99Diabete1/146 (0.7%)0/63 (0%)1/83 (1.2%)NE0.99Immusuppressive therapy7/146 (4.8%)4/63 (6.3%)3/83 (3.6%)1.81 [0.38;9.47]0.45Current pregnancy1/111 (0.9%)0/52 (0%)1/59 (1.7%)NE0.99Type of expositionContact with > 1 index26/146 (17.8%)13/63 (20.6%)13/83 (15.7%)1.4 [0.59 ;3.3]0.44Types of index subjectContacts with infected HW(s) only80/146 (54.8%)27/63 (42.9%)53/83 (63.9%)1 (ref)–1 (ref)–Contacts with infected patient66/146 (45.2%)36/63 (57.1%)30/83 (36.1%)2.36 [1.21;4.65]0.012.62 [1.24;5.71]0.013Maximal SARS-CoV-2 viral load in the index subject9.3 [7.5;10.8] (N = 145)10 [7.6;10.8] (N = 62)8.7 [7.5;10.8] (N = 83)1.1 [0.93;1.31]0.25Cumulated length of exposure > 30 min98/143 (68.5%)38/61 (62.3%)60/82 (73.2%)0.61 [0.3;1.23]0.17Exposure to infected patient (N = 66)Care during an aerosol-generating procedure6/66 (9.1%)3/36 (8.3%)3/30 (10%)0.82 [0.14;4.73]0.81Care without aerosol-generating procedure55/66 (83.3%)30/36 (83.3%)25/30 (83.3%)1 [0.26;3.7]1Presence in the patient's room during an aerosol-generating procedure22/66 (33.3%)13/36 (36.1%)9/30 (30%)1.32 [0.47;3.8]0.6Other type of contact12/66 (18.2%)10/36 (27.8%)2/30 (6.7%)5.38 [1.27;37.23]0.04Exposure to a SARS-CoV-2-infected HCW (N = 92)Face-to-Face discussion86/92 (93.5%)31/34 (91.2%)55/58 (94.8%)0.56 [0.1;3.2]0.5Participation in a joint meeting25/92 (27.2%)9/34 (26.5%)16/58 (27.6%)0.95 [0.35;2.43]0.91Lunch sharing20/92 (21.7%)6/34 (17.6%)14/58 (24.1%)0.67 [0.22;1.89]0.47Other type of contact9/92 (9.8%)3/34 (8.8%)6/58 (10.3%)0.84 [0.17;3.42]0.81 Open table in a new tab Overall, 24 /146 contact subjects (16.4%, 95%CI [11.0%−23.7%]) had at least one SARS-CoV-2-positive nasopharyngeal swab; 16/146 contact subjects (10.9%) had positive serology at inclusion which did not respond to the seroconversion definition, revealing a pre-existing infection and 31 additional contact subjects (21.2%, 95%CI [15.1%−28.9%]) exhibited a seroconversion at D30. Based on self-administered questionnaires, 59/146 contact subjects (40.4%, 95%CI [32.5%−48.9%]) met the definition of a clinical infection Fig. 1. Seven out of 24 subjects with positive SARS-CoV-2 nasopharyngeal RT-PCR had a positive RT-PCR before the symptoms onset; the first positive nasopharyngeal RT-PCR was observed as early as six days before symptoms onset. At day 30, 63/146 contacts (43.2%, 95%CI [35.1%−51.6%]) had SARS-CoV-2 infection (confirmed in 35 (23.9%, 95%CI [17.5%; 31.9%]), and possible in 28 (19.2%, 95%CI [13.3%; 26.7%])). In the multivariable analysis, the variables associated with SARS-CoV-2 infection were being a non-caregiver HW (aOR = 4.1, 95%CI [1.4; 12.2], p = 0.010) and being exposed to a SARS-CoV-2-infected patient (aOR = 2.6, 95%CI [1.2; 5.7], p = 0.013) rather to an infected colleague (Table 1). Following universal masking for HWs on March, 18th in our hospital, high-risk exposure to SARS-CoV-2-positive patients dropped by 4 and high-risk exposure to SARS-CoV-2-positive colleagues became predominant, making colleagues-to-colleagues transmission a potentially major route of infection6Contejean A. Leporrier J. Canoui E. Alby-Laurent F. Lafont E. Beaudeau L. et al.Comparing dynamics and determinants of SARS-CoV-2 transmissions among health care workers of adult and pediatric settings in central Paris.Clin Infect Dis. Jul 15 2020; (PubMed PMID:32663849)PubMed Google Scholar. Of note, none of the exposures between a HW and a SARS-CoV-2 infected patient occurred in the front-line services where the mask was worn by all caregivers from the beginning of the epidemic. These exposures occurred, prior to universal masking, in second-line services in which patients had not been previously identified as COVID-19. The profession of the contact subjects was associated with infection, but we did not find any association with the type of activities of the HWs. The 10.9% rate of HWs with SARS-Cov-2 antibodies at inclusion revealing a pre-existing infection while they were not working in front-line services, is close to the seroprevalence of 8.8% reported in the Paris area in the general population during this period7Santé Publique France. Point épidémiologie hebdomadaire. https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-et-infections-respiratoires/infection-a-coronavirus/documents/bulletin-national/covid-19-point-epidemiologique-du-23-juillet-2020. Accessed July 28, 2020.Google Scholar,8Le Vu S. Jones G. Anna F. Rose T. Richard J. Bernard-Stoecklin S. et al.Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance.medRxiv. 2020; https://doi.org/10.1101/2020102020213116Crossref Google Scholar. In addition to these HWs already infected at inclusion, 31 others (21.2% of the total population) seroconverted at day 30. We cannot state with certainty that contacts meeting the definition of confirmed infection acquired their infection as a result of the exposure leading to their inclusion in the study. There are several arguments in favor of the link between exposure and infection: the RT-PCR positivity within 12 days after contact, the chronology of symptom onset after contact, and the seroconversion rate observed within the 30 days following the exposure, which is much higher than that observed in the community between March and May 20207Santé Publique France. Point épidémiologie hebdomadaire. https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-et-infections-respiratoires/infection-a-coronavirus/documents/bulletin-national/covid-19-point-epidemiologique-du-23-juillet-2020. Accessed July 28, 2020.Google Scholar, 8Le Vu S. Jones G. Anna F. Rose T. Richard J. Bernard-Stoecklin S. et al.Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance.medRxiv. 2020; https://doi.org/10.1101/2020102020213116Crossref Google Scholar. In addition, the subjects included were counseled to strictly adhere to protective measures to avoid any chain of transmission during the D0-D30 period, limiting the risk of further exposure. All together, the rate of transmission observed in HWs after high-risk exposure, which could be as large as 43%, and close to a recent report9Houlihan C.F. Vora N. Byrne T. Lewer D. Kelly G. Heaney J. et al.Pandemic peak SARS-CoV-2 infection and seroconversion rates in London frontline health-care workers.Lancet. Jul 25 2020; 396 (PubMed PMID:32653078): e6-e7Abstract Full Text Full Text PDF PubMed Scopus (145) Google Scholar, strengthens the conclusion that universal masking of HW, both during contacts with patients and colleagues, and at all times, as soon as the epidemic has been identified, is essential to prevent HWs infection and maintain hospital capacities during outbreaks10Houghton C. Meskell P. Delaney H. Smalle M. Glenton C. Booth A. et al.Barriers and facilitators to healthcare workers' adherence with infection prevention and control (IPC) guidelines for respiratory infectious diseases: a rapid qualitative evidence synthesis.Cochrane Database Syst Rev. Apr 21 2020; 4 (PubMed PMID:32315451)CD013582PubMed Google Scholar. CoVCONTACT study group Principal investigator: Duval Xavier Steering Committee: Burdet Charles, Duval Xavier, Lina Bruno, Tubiana Sarah, Van Der Werf Sylvie CoV-CONTACT Clinical Centers: Abad Fanny, Abry Dominique, Alavoine Loubna, Allain Jean-Sébastien, Amiel-Taieb Karline, Audoin Pierre, Augustin Shana, Ayala Sandrine, Bansard Hélène, Bertholon Fréderique,Boissel Nolwenn, Botelho-Nevers Elisabeth, Bouiller Kévin, Bourgeon Marilou, Boutrou Mathilde, Brick Lysiane, Bruneau Léa, Caumes Eric, Chabouis Agnès, Chan Thien Eric, Chirouze Catherine, Coignard Bruno, Costa Yolande, Costenoble Virginie, Cour Sylvie, Cracowski Claire, Cracowski Jean Luc, Deplanque Dominique, Dequand Stéphane, Desille-Dugast Mireille, Desmarets Maxime, Detoc Maelle, Dewitte Marie, Djossou Felix, Ecobichon Jean-Luc, Elrezzi Elise, Faurous William, Fortuna Viviane, Fouchard Julie, Gantier Emilie, Gautier Céline, Gerardin Patrick, Gerset Sandrine, Gilbert Marie, Gissot Valérie, Guillemin Francis, Hartard Cédric, Hazevis Béatrice, Hocquet Didier, Hodaj Enkelejda, Ilic-Habensus Emila, Jeudy A, Jeulin Helene, Kane Maty,Kasprzyk Emmanuelle, Kikoine John, Laine Fabrice, Laviolle Bruno, Lebeaux David, Leclercq Anne, Ledru Eric, Lefevre Benjamin, Legoas Carole, Legrand Amélie, Legrand Karine, Lehacaut Jonathan, Lehur Claire, Lemouche Dalila, Lepiller Quentin, Lepuil Sévérine, Letienne Estelle, Lucarelli Aude, Lucet Jean-Christophe, Madeline Isabelle, Maillot Adrien, Malapate Catherine, Malvy Denis, Mandic Milica, Marty-Quinternet Solène, Meghadecha Mohamed, Mergeay-Fabre Mayka, Mespoulhe Pauline, Meunier Alexandre, Migaud Maria-Claire, Motiejunaite Justina, Nathalie Gay, Nguyen Duc, Oubbea Soumaya, Pagadoy Maïder, Paris Adeline, Paris Christophe, Payet Christine, Peiffer-Smadja Nathan, Perez Lucas, Perreau Pauline, Pierrez Nathalie, Pistone Thierry, Postolache Andreea, Rasoamanana Patrick, Reminiac Cécile, Rexah Jade, Roche-Gouanvic Elise, Rousseau Alexandra, Schoemaecker Betty, Simon Sandrine, Soler Catherine, Somers Stéphanie, Sow Khaly, Tardy Bernard, Terzian Zaven, Thy Michael, Tournier Anne, Tyrode Sandrine, Vauchy Charline, Verdon Renaud, Vernet Pauline, Vignali Valérie, Waucquier Nawal Coordination and statistical analyses: Burdet Charles, Do Thi Thu Huong, Laouénan Cédric, Mentre France, Pauline Manchon, Tubiana Sarah, Dechanet Aline, Letrou Sophie, Quintin Caroline, Frezouls Wahiba Virological lab: Le Hingrat Quentin, Houhou Nadhira, Damond Florence, Descamps Dianes, Charpentier Charlotte, Visseaux Benoit, Vabret Astrid, Lina Bruno, Bouscambert Maud, Van Der Werf Sylvie, Behillil Sylvie, Gaillanne Laurence, Benmalek Nabil, Attia Mikael, Barbet Marion, Demeret Caroline, Rose Thierry, Petres Stéphane, Escriou Nicolas, Barbet Marion, Petres Stéphane, Escriou Nicolas, Goyard Sophie Biological center: Kafif Ouifiya, Piquard Valentine, Tubiana Sarah Partners: RECOVER, REACTING, Santé Publique France (Coignard Bruno, Mailles Alexandra), Agences régionales de santé (Simondon Anne, Dreyere Marion, Morel Bruno, Vesval Thiphaine) Sponsor: Inserm Amat Karine, Ammour Douae, Aqourras Khadija, Couffin-Cadiergues Sandrine, Delmas Christelle, Desan Vristi, Doute Jean Michel, Esperou Hélène, Hendou Samia, Kouakam Christelle, Le Meut Guillaume, Lemestre Soizic, Leturque Nicolas, Marcoul Emmanuelle, Nguefang Solange, Roufai Layidé Genetic: Laurent Abel, Sophie Caillat-ZucmanClinicalTrial. Gov identification number: NCT0425989" @default.
• W3128448500 created "2021-02-15" @default.
• W3128448500 creator A5006680048 @default.
• W3128448500 creator A5007476252 @default.
• W3128448500 creator A5010374583 @default.
• W3128448500 creator A5012706940 @default.
• W3128448500 creator A5016854254 @default.
• W3128448500 creator A5025744689 @default.
• W3128448500 creator A5032223222 @default.
• W3128448500 creator A5032229903 @default.
• W3128448500 creator A5033930684 @default.
• W3128448500 creator A5037100913 @default.
• W3128448500 creator A5039539798 @default.
• W3128448500 creator A5045655223 @default.
• W3128448500 creator A5047124634 @default.
• W3128448500 creator A5059376092 @default.
• W3128448500 creator A5059602594 @default.
• W3128448500 creator A5059979662 @default.
• W3128448500 creator A5062909007 @default.
• W3128448500 creator A5063863918 @default.
• W3128448500 creator A5064601780 @default.
• W3128448500 creator A5064974381 @default.
• W3128448500 creator A5069063356 @default.
• W3128448500 creator A5080451499 @default.
• W3128448500 creator A5086106039 @default.
• W3128448500 date "2021-05-01" @default.
• W3128448500 modified "2023-10-16" @default.
• W3128448500 title "High-risk exposure without personal protective equipment and infection with SARS-CoV-2 in-hospital workers - The CoV-CONTACT cohort" @default.
• W3128448500 cites W3013653866 @default.
• W3128448500 cites W3033399633 @default.
• W3128448500 cites W3036760331 @default.
• W3128448500 cites W3040252386 @default.
• W3128448500 cites W3042161179 @default.
• W3128448500 doi "https://doi.org/10.1016/j.jinf.2021.01.026" @default.
• W3128448500 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7857039" @default.
• W3128448500 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33545165" @default.
• W3128448500 hasPublicationYear "2021" @default.
• W3128448500 type Work @default.
• W3128448500 sameAs 3128448500 @default.
• W3128448500 citedByCount "5" @default.
• W3128448500 countsByYear W31284485002020 @default.
• W3128448500 countsByYear W31284485002021 @default.
• W3128448500 countsByYear W31284485002022 @default.
• W3128448500 countsByYear W31284485002023 @default.
• W3128448500 crossrefType "journal-article" @default.
• W3128448500 hasAuthorship W3128448500A5006680048 @default.
• W3128448500 hasAuthorship W3128448500A5007476252 @default.
• W3128448500 hasAuthorship W3128448500A5010374583 @default.
• W3128448500 hasAuthorship W3128448500A5012706940 @default.
• W3128448500 hasAuthorship W3128448500A5016854254 @default.
• W3128448500 hasAuthorship W3128448500A5025744689 @default.
• W3128448500 hasAuthorship W3128448500A5032223222 @default.
• W3128448500 hasAuthorship W3128448500A5032229903 @default.
• W3128448500 hasAuthorship W3128448500A5033930684 @default.
• W3128448500 hasAuthorship W3128448500A5037100913 @default.
• W3128448500 hasAuthorship W3128448500A5039539798 @default.
• W3128448500 hasAuthorship W3128448500A5045655223 @default.
• W3128448500 hasAuthorship W3128448500A5047124634 @default.
• W3128448500 hasAuthorship W3128448500A5059376092 @default.
• W3128448500 hasAuthorship W3128448500A5059602594 @default.
• W3128448500 hasAuthorship W3128448500A5059979662 @default.
• W3128448500 hasAuthorship W3128448500A5062909007 @default.
• W3128448500 hasAuthorship W3128448500A5063863918 @default.
• W3128448500 hasAuthorship W3128448500A5064601780 @default.
• W3128448500 hasAuthorship W3128448500A5064974381 @default.
• W3128448500 hasAuthorship W3128448500A5069063356 @default.
• W3128448500 hasAuthorship W3128448500A5080451499 @default.
• W3128448500 hasAuthorship W3128448500A5086106039 @default.
• W3128448500 hasBestOaLocation W31284485001 @default.
• W3128448500 hasConcept C116675565 @default.
• W3128448500 hasConcept C126322002 @default.
• W3128448500 hasConcept C159047783 @default.
• W3128448500 hasConcept C166888038 @default.
• W3128448500 hasConcept C177713679 @default.
• W3128448500 hasConcept C194828623 @default.
• W3128448500 hasConcept C201903717 @default.
• W3128448500 hasConcept C2779134260 @default.
• W3128448500 hasConcept C2780668467 @default.
• W3128448500 hasConcept C2987845665 @default.
• W3128448500 hasConcept C3006700255 @default.
• W3128448500 hasConcept C3007834351 @default.
• W3128448500 hasConcept C3008058167 @default.
• W3128448500 hasConcept C524204448 @default.
• W3128448500 hasConcept C545542383 @default.
• W3128448500 hasConcept C71924100 @default.
• W3128448500 hasConcept C72563966 @default.
• W3128448500 hasConceptScore W3128448500C116675565 @default.
• W3128448500 hasConceptScore W3128448500C126322002 @default.
• W3128448500 hasConceptScore W3128448500C159047783 @default.
• W3128448500 hasConceptScore W3128448500C166888038 @default.
• W3128448500 hasConceptScore W3128448500C177713679 @default.
• W3128448500 hasConceptScore W3128448500C194828623 @default.
• W3128448500 hasConceptScore W3128448500C201903717 @default.
• W3128448500 hasConceptScore W3128448500C2779134260 @default.
• W3128448500 hasConceptScore W3128448500C2780668467 @default.
• W3128448500 hasConceptScore W3128448500C2987845665 @default.
• W3128448500 hasConceptScore W3128448500C3006700255 @default.
• W3128448500 hasConceptScore W3128448500C3007834351 @default.

• next